Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in PAH Patients Intolerant to Other ERAs
NCT00423592Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2005
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Gilead Sciences. Started May 2005; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00423592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423592.